NASDAQ · ZVRA
Zevra Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ZVRA: Nov 03, 2026
Zevra Therapeutics, Inc. Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.14. The reported EPS for the same quarter last year was $-0.01.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.14 | $0.15 | $0.11 | 3 |
| Dec 2026 | $0.16 | $0.18 | $0.13 | 3 |
| Mar 2027 | $0.20 | $0.20 | $0.20 | 1 |
| Jun 2027 | $0.25 | $0.25 | $0.25 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · MarketBeat · Zacks- BNK Invest · Aug 26, 3:19 PM EDTNotable Wednesday Option Activity: ZVRA, KOD, PENLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Zevra Therapeutics, Inc (Symbol: ZVRA), where a total volume of 8,827 contracts has been traded thus far today, a contract volume which is representative of appr
- RTTNews · Aug 25, 7:57 AM EDTZevra To Present Long-Term MIPLYFFA Data In Niemann-Pick Disease At SSIEM 2026(RTTNews) – Zevra Therapeutics, Inc. (ZVRA) announced that it will present two posters featuring long-term real-world data on MIPLYFFA (arimoclomol) in patients with Niemann-Pick disease type C (NPC) at the 2026 SSIEM Annual Symposium.
- MarketBeat · Aug 6, 4:04 AM EDTZevra Therapeutics Q2 Earnings Call HighlightsZevra Therapeutics (NASDAQ:ZVRA) reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA. Net U.S. revenue for MIPLYFFA totaled $30.2 million during
- Zacks · Aug 5, 8:35 PM EDTZevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass EstimatesZevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 31, 7:10 AM EDTOno Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top EstimatesOno Pharmaceutical Co. (OPHLF) delivered earnings and revenue surprises of +60.00% and +5.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 25, 12:23 AM EDTZevra To Appeal EMA's Negative Opinion On Arimoclomol For Niemann-Pick Disease Type C(RTTNews) – Zevra Therapeutics, Inc. (ZVRA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the company's Marketing Authorization Application for Arimoclomol for the treatment of Nie
- BNK Invest · Jul 24, 3:43 PM EDTNoteworthy Friday Option Activity: SPCX, ZVRA, CAPRAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Space Exploration Technologies Corp (Symbol: SPCX), where a total of 694,074 contracts have traded so far, representing approximately 69.4 million underlying shares. Tha
- RTTNews · Jun 24, 2:08 AM EDTZevra Publishes Promising Phase 2/3 Data For MIPLYFFA In Treating Niemann-Pick Type C(RTTNews) – Zevra Therapeutics Inc. (ZVRA), a commercial-stage company, on Tuesday announced publication of encouraging Phase 2/3 data for MIPLYFFA in treating Niemann-Pick type C disease in pediatric patients of two years or younger. The results were published in the journal of
- RTTNews · Jun 8, 10:41 PM EDTTop Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads(RTTNews) – Today's top gainers include Tango Therapeutics, following encouraging pancreatic cancer trial data; Aspire Biopharma, ahead of upcoming milestones; Alvotech, after FDA acceptance of its interchangeable biosimilar to Entyvio for review; and Zevra Therapeutics, on actio
- MarketBeat · May 7, 6:07 AM EDTZevra Therapeutics Q1 Earnings Call HighlightsZevra Therapeutics (NASDAQ:ZVRA) reported first-quarter 2026 net revenue of $36.2 million, up 78% from the prior-year period, as the company highlighted continued adoption of its Niemann-Pick disease type C (NPC) therapy MIPLYFFA in the U.S., growth in its global expanded access
- The Motley Fool · May 6, 6:45 PM EDTZevra (ZVRA) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 6, 6:30 PM EDTZevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass EstimatesZevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +184.36% and +15.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Zevra Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.